Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure. Overall survival (OS) in ...

Learn how to build and test narrowboat steps with this companionway tutorial, covering precise measurements, secure installation, and safety checks. Perfect for DIY narrowboat owners aiming to improve ...

Angelina Jolie declared that her double mastectomy scars “are a choice” she is “grateful” she was able to make. “I’ve always been someone more interested in the scars and the life that people carry,” ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

LITTLE ROCK, Ark. (KATV) — It’s a question so many women have asked: "If my mother had breast cancer, will I get it too?" But doctors say knowledge is power, and that power could save your life. UAMS ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

NOTCH1 mutations, found in 20% of CLL cases, are associated with poor outcomes in chemotherapy but not yet in treatment guidelines. A retrospective analysis showed improved PFS for NOTCH1-mutated CLL ...

Abstract: Mutation testing is a potentially effective method to assess test suite adequacy. Researchers have made mutation testing more computationally efficient, and new frameworks are regularly ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

The SERENA-6 trial focused on ESR1 mutation detection in metastatic HR-positive, HER2-negative breast cancer to extend first-line treatment efficacy. Serial liquid biopsies were used to identify ESR1 ...